8.52012

Fmoc-Lys(Boc)-OH

Novabiochem^®

• 동의어(들): Fmoc-Lys(Boc)-OH, N-α-Fmoc-N-ε-t.-Boc-L-lysine
• 실험식(Hill 표기법): C₂₆H₃₂N₂O₆
• CAS Number: 71989-26-9
• Molecular Weight: 468.54
• MDL number: MFCD00037138
• UNSPSC 코드: 12352209
• EC 인덱스 번호: 276-256-4
• NACRES: NA.22

속성

• Quality Level: 400
• 제품 라인: Novabiochem^®
• 분석: ≥98% (TLC); ≥98.0% (acidimetric); ≥99.0% (HPLC)
• 형태: powder
• 반응 적합성: reaction type: Fmoc solid-phase peptide synthesis
• 제조업체/상표: Novabiochem^®
• mp: 123-130 °C
• 응용 분야: peptide synthesis
• 작용기: Boc; amine
• 저장 온도: 2-30°C
• InChI: 1S/C26H32N2O6/c1-26(2,3)34-24(31)27-15-9-8-14-22(23(29)30)28-25(32)33-16-21-19-12-6-4-10-17(19)18-11-5-7-13-20(18)21/h4-7,10-13,21-22H,8-9,14-16H2,1-3H3,(H,27,31)(H,28,32)(H,29,30)
• InChI key: UMRUUWFGLGNQLI-UHFFFAOYSA-N

설명

일반 설명

High purity Fmoc-protected amino acid for research and process production of peptides, with very low levels of dipeptide, free-amino acids and acetic acid impurities. Standard building block for introduction of lysine amino-acid residues by Fmoc SPPS

Associated Protocols and Technical Articles
Fmoc-amino acids for Peptide Production
Cleavage and Deprotection Protocols for Fmoc SPPS

애플리케이션

• Pharmacokinetics of Tizanidine in Muscle Spasticity: A comprehensive review on Tizanidine covers its pharmacological advancements and therapeutic applications, particularly focusing on muscle spasticity. This highlights the relevance of high-purity Tizanidine-D₄ hydrochloride in creating precise and reproducible pharmacokinetic profiles (Zhu et al., 2024).


• Stable Isotope-Labeled Tizanidine for Bioanalytical Method Development: The development and validation of bioanalytical methods for monitoring drug interactions and metabolism extensively utilize Tizanidine-D₄ HCl. The isotopic labeling aids in accurate quantification and identification, enhancing the reliability of pharmacokinetic and pharmacodynamic studies (Chen et al., 2024).


• Tizanidine-D₄ Hydrochloride Solution for Receptor Binding Studies: The application of Tizanidine-D₄ in receptor binding studies is inferred from research exploring its withdrawal effects and the pharmacological interventions required, suggesting its utility in detailed receptor interaction studies in clinical settings (Tanimura et al., 2024).

결합

Replaces: 04-12-1026

분석 메모

Colour (visual): white to off white
Appearance of substance (visual): powder
Colour index (0,5 M in DMF): ≤ 150 Hazen
Identity (IR): passes test
Enantiomeric purity: ≥ 99.8 % (a/a)
Purity (HPLC): ≥ 99.0 % (a/a)
Fmoc-ß-Ala-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-ß-Ala-Lys(Boc)-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-Lys(Boc)-Lys(Boc)-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-Lys-OH (HPLC): ≤ 0.1 % (a/a)
Assay free amino acid (GC): ≤ 0.2 %
Purity (TLC(011A)): ≥ 98 %
Purity (TLC(0811)): ≥ 98 %
Solubility (25 mmole in 50 ml DMF): clearly soluble
Assay (acidimetric): ≥ 98.0 %
Water (K. F.): ≤ 2.0 %
Ethyl acetate (HS-GC): ≤ 0.5 %
Acetate (IC): ≤ 0.02 %

To see the solvent systems used for TLC of Novabiochem^® products please click here.

법적 정보

Novabiochem is a registered trademark of Merck KGaA, Darmstadt, Germany

안전성 정보

• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable